Detection of sentinel lymph node (SLN) using photoacoustic imaging is an emerging technique for noninvasive axillary staging of breast cancer. Due to the absence of intrinsic contrast inside the lymph nodes, exogenous contrast agents are used for photoacoustic detection. In this work, we have demonstrated near infrared detection of SLN with gold nanobeacons (GNBs) providing the photoacoustic contrast in a rodent model. We found that size dictates the in vivo characteristics of these nanoparticles in SLN imaging. Larger nanobeacons with high payloads of gold were not as efficient as smaller size nanobeacons with lower payloads for this purpose. Colloidal GNBs were designed as a nanomedicine platform with ''soft'' nature that is amenable to bio-elimination, an essential feature for in vivo efficacy and safety. The GNBs were synthesized as lipid-or polymer-encapsulated colloidal particles incorporating tiny gold nanoparticles (2-4 nm) in three tunable sizes (90 nm, 150 nm and 290 nm). Smaller GNBs were noted trafficking through the lymphatic system and accumulating more efficiently in the lymph nodes in comparison to the bigger nanoagents. At 20 min, the GNBs reached the SLN and were no longer observed within the draining lymphatic vessel. Within 1 h post-injection, the contrast ratio of the lymph nodes with the surrounding blood vessels was 9:1. These findings were also supported by analytical measurements of the ex vivo tissue samples. Results indicate that cumulative nanoparticle deposition in lymph nodes is size dependent and that high payloads of gold, although offering greater contrast in vitro, may yield nanoagents with poor intradermal migration and lymphatic transport characteristics.
Introduction
In clinics, patients with breast cancer and melanoma presently undergo invasive sentinel lymph node biopsy (SLNB) to stage metastases. However, even in experienced hands the identification rates and sensitivities of this technique are less than 95% [1] [2] [3] . Moreover, SLNB can lead to seroma formation, lymphedema, sensory nerve injury, and limitation in the range of motion [4] . Therefore, an alternative noninvasive method to identify sentinel lymph nodes (SLNs) in conjunction with either minimally invasive percutaneous fine-needle aspiration biopsy (FNAB) or completely noninvasive molecular techniques will open a whole new prospect of noninvasive axillary staging for breast cancer. Noninvasive imaging modalities, e.g., magnetic resonance imaging (MRI), optical imaging, photoacoustic tomography (PAT) in combination with nanoparticle-based contrast agents show promise in improved detection of metastases. Among these, PAT is a hybrid biomedical imaging modality, which synergizes the high contrast of optical imaging with the high resolution of ultrasonic imaging. PAT has been used for various biomedical applications, such as breast cancer imaging, brain structural and functional imaging, bloodoxygenation and hemoglobin monitoring, tumor angiogenesis, and, recently molecular imaging [5] [6] [7] [8] [9] [10] [11] [12] [13] . The success of PAT with noninvasive SLNs mapping can be considered as a giant step towards breast cancer staging.
Noninvasive mapping of SLNs has been explored with photoacoustic (PA) imaging using various contrast agents, such as methylene blue dye, single-walled carbon nanotubes, gold nanocages, and gold nanorods [14] [15] [16] [17] . While these approaches have seen some preliminary success in laboratory animals, it is still poorly understood how nanoparticles traverse through the lymphatic vessels and migrate into the nodes. Clearly, there is a critical unmet clinical need, and delineating this transport mechanism will further improve detection sensitivities, drug delivery efficiencies, and reduce off-target toxicity of engineered nanostructures.
We recently reported the development of gold nanobeacons (GNB 160 s) designed for noninvasive detection of vascular biosignatures, e.g., fibrin, using photoacoustic tomography [18] . Colloidal gold nanobeacons represent a nanomedicine platform that have a ''soft'' nature and are amenable to bio-elimination, which are essential features for in vivo efficacy and safety. Liganddirected GNB 160 s were found to deliver ten-fold higher PA signal over blood (i.e., hemoglobin) when targeted to fibrin clots. We hypothesize that the cumulative nanoparticle accumulation in lymph nodes is size dependent and that high payloads of metal may yield nanoparticles with unsatisfactory intradermal migration and lymphatic transport characteristics.
Materials and methods

General experimental procedure
Unless otherwise listed, all solvents and reagents were purchased from Aldrich Chemical Co. (St. Louis, MO) and used as received. Anhydrous chloroform and methanol were purchased from Aldrich Chemical Co. Poly(styrene-b-acrylic acid) [19] [20] [21] [22] (PS-b-PAA) was purchased from Polymer Source Inc. (Montreal, Canada). Biotinylated-dipalmitoylphosphatidylethanolamine and high purity egg yolk phosphatidylcholine were purchased from Avanti Polar Lipids, Inc. Cholesterol and octylthiol-coated gold nanoparticles were purchased and used as received from Aldrich Chemical Co. (St. Louis, MO). Sorbitan monolaurate was purchased from Aldrich. Argon and nitrogen (Ultra High Purity: UHP, 99.99%) were used for storage of materials. The Spectra/Por membrane (Cellulose MWCO: 20,000 Da) used for dialysis was obtained from Spectrum Medical Industries, Inc. (Laguna Hills, CA).
Preparation of L-GNB 90
In a typical experimental procedure, octanethiol coated gold nanoparticles (2-4 nm, Aldrich Inc., 2% w/v) in toluene (100 mg) are suspended in sorbitan sesquioleate (4 mL, 2 mol%) and vigorously vortexed to homogeneity. The suspension was filtered through a small bed of cotton. The solvent was evaporated under reduced pressure at 45 C. The surfactant co-mixture included high purity egg yolk phosphatidylcholine (91 mol%, 380 mg), cholesterol (8 mol%, 17.39 mg), and biotinylated-dipalmitoylphosphatidylethanolamine (1 mol%, 6.2 mg). The surfactant co-mixture was dissolved in chloroform, evaporated under reduced pressure, dried in a 40 C vacuum oven overnight, and dispersed into water by probe sonication. This suspension was combined with the gold nanoparticle-suspended sorbitan sesquioleate mixture (20% v/v), distilled deionized water (15.23 mL, 77.3% w/v), and glycerin (0.37 mL, 1.7% w/v). The mixture was continuously processed thereafter at 20,000 PSI for 4 min with an S110 Microfluidics emulsifier (Microfluidics) at 4 C. The nanobeacons were dialyzed against water using a 20,000 Da MWCO cellulose 
Preparation of P-GNB 290
In a typical experimental procedure, octanethiol coated gold nanoparticles (2-4 nm, Aldrich Inc.) in toluene were suspended in sorbitan monolaurate (1 mL, 5 mol%) and vigorously vortexed to homogeneity. The suspension was filtered through a small bed of cotton. The amphiline PS-b-PAA [19] [20] [21] [22] (Mn Â 10
À3
: 0.8-b-29.3 polydispersity index: PDI ¼ 1.18, 0.0034 mmol, 104.0 mg, 0.5 mol%) was dissolved in a mixture of methanol and chloroform (4:1), filtered through a small bed of cotton, evaporated under reduced pressure at 50 C, dried in a 40 C vacuum oven for 6 h, and dispersed into water by probe sonication until a clear suspension was obtained. This suspension (10 mL) was combined with the gold nanoparticlesuspended polysorbate mixture (1 mL, 5 mol%), distilled deionized water (8.45 mL, 0.2 mM), and glycerin (0.45 mL). The mixture was then briefly probe sonicated at ambient temperature followed by continuous processing at 20,000 PSI (137.9 MPa) for 4 min with an S110 Microfluidics emulsifier (Microfluidics) at 4 C. The nanobeacons were purified by exhaustive dialysis against deionized water using 20 kDa MW CO cellulosic membrane. The nanoparticles were recovered and passed 
Measurements
Dynamic light scattering measurements
Instrument and method: Hydrodynamic diameter distribution and distribution averages for the GNB and controls in aqueous solutions were determined by dynamic light scattering. Hydrodynamic diameters were determined using a Brookhaven Instrument Co. (Holtsville, NY) Model Zeta Plus particle size analyzer. Measurements were made following dialysis (MWCO 10 kDa dialysis tubing, Spectrum Laboratories, Rancho Dominguez, CA) of GNB suspensions into deionized water (0.2 mM). Nanobeacons were dialyzed into water prior to analysis. Scattered light was collected at a fixed angle of 90 . A photomultiplier aperture of 400 mm was used, and the incident laser power was adjusted to obtain a photon counting rate between 200 and 300 kcps. Only measurements for which the measured and calculated baselines of the intensity autocorrelation function agreed to within þ0.1% were used to calculate nanoparticle hydrodynamic diameter values. All determinations were made in multiples of five consecutive measurements. m ¼ 3z/h, where 3 and h are the dielectric constant and the absolute viscosity of the medium, respectively. Measurements of z were reproducible to within AE4 mV of the mean value given by 16 determinations of 10 data accumulations.
Electrophoretic potential measurements
Atomic force microscopy measurements
Instrument and method: A Digital Instruments Dimension 3000 series AFM (calibration date 08/2008) and standard Veeco tapping mode silicon probes w/PtIr coating were used for scanning the samples.
In a typical methodology, aqueous suspensions of GNB samples were dried in a class 10,000-clean room on a clean glass slide for 3 h. Once dried, samples were placed on the AFM and scanned. Pertinent scanning parameters were as follows: Resonant frequency (probe): 60-80 kHz; Example of tip velocity: (4 um/s for 2 um), (15 um/s for 5 um), (30 um/s for 10 um). Aspect ratio: 1:1; Lift height: 20 nm; Resolution: 512 samples/line, 256 lines. The average particle height (H av ) values and standard deviations were generated from the analyses of a minimum of 100 particles from three micrographs.
Inductively coupled plasma-optical emission spectroscopy (ICP-OES)
Instrument and method: The iodine and bismuth contents of cROMP were analyzed by inductively coupled plasma-optical emission spectroscopy (ICP-MS, SOP7040, Rev 9) conducted at the Bodycote, West Coast Analytical Service (WCAS), Santa Fe Springs, CA. Briefly, the samples were analyzed by a Leeman Labs Direct Reading Echelle ICP-MS, or a DRE (Direct Reading Echelle) instrument which was designed to handle sub-ppm to percent level metal concentrations. DRE consists of a 2 dimensional, high resolution Echelle grating which precisely and reliably locate any peak in the ICP spectrum.
Photoacoustic imaging system
Instrument and method: A reflection-mode PA imaging system [23] was used for all PA experiments. A tunable Ti:sapphire laser (LT-2211A, LOTIS TII) pumped by Qswitched Nd:YAG (LS-2137, LOTIS II) laser was the light source, providing <15 ns pulse duration and a 10-Hz pulse repetition rate. A dark-field ring-shaped illumination was used [24] . The light energy on the sample surface was controlled to conform to the American National Standards Institute (ANSI) standard for maximum permissible exposure (MPE) [25] . A 5-MHz central frequency, spherically focused (2.54 cm focus length, 1.91 cm diameter active area element, and 72% bandwidth) ultrasonic transducer (V308, Panametrics-NDT) was used to acquire the generated PA signals. The signal was then amplified by a low-noise amplifier (5072PR, Panametrics-NDT), and recorded using a digital oscilloscope (TDS 5054, Tektronix) with a 50 mega-sampling rate. PA signal fluctuations due to pulse-to-pulse energy variation were compensated by signals from a photodiode (DET110, Thorlabs), which sampled the energy of each laser pulse.
A linear translation stage (XY-6060, Danaher Motion) was used for raster scanning to obtain three-dimensional (3-D) PA data. A computer controlled the stage and synchronized it with the data acquisition. To shorten the data acquisition time, a continuous scan was used without signal averaging. An A-line (A-scan) was the PA signal obtained along the depth direction at a single point. 
Animal and drug information
Guidelines on the care and the use of laboratory animals at Washington University in St. Louis were followed for all animal experiments. Adult Sprague Dawley rats with body weights ranging from 200 to 300 g were used for the in vivo studies. Initial anesthetization of the rat was done using a mixture of ketamine (85 mg/kg) and xylazine (15 mg/kg). The animal was maintained with 1.5-3% isoflurane in oxygen on a ventilator for approximately 2 h during the SLN imaging, which included a control image (pre-injection PA signal), followed by post-injection PA image at an interval of w20 min after injection of GNB 160 s/L-GNB 90 s/P-GNB 290 s. For the noninvasive PA imaging, the hair on the region of interest of the rat was gently removed before imaging, using a commercial hair-removal lotion. A 0.15 mL of GNB 160 s/L-GNB 90 s/P-GNB 290 s was intradermally injected on a left/right forepaw pad, depending on which side was imaged. PA images were acquired after the administration of GNBs. During the image acquisition, anesthesia was maintained using vaporized isoflurane (1 L/min oxygen and 0.75% isoflurane, Euthanex Corp.), and a pulse oximeter (NONIN Medical INC., 8600 V) was used to monitor the vitals. If needed, 8 mL of 0.9% saline was administered to the rat for hydration. After image acquisition, the animal was euthanized by pentobarbital overdose.
Results and discussion
In the first phase of our experiment, the potential of SLN imaging with GNB 160 [D av (DLS): 155 AE 11 nm, ICP-OES: 6120 gold/nanobeacons] was tested in a rodent model. Lymph node imaging was possible with GNB 160 (5 mM) (Fig. 3A and B) , however with eight times diluted GNB 160 s (w600 nM), SLNs were not visible (see supporting information for more details). The study produced mixed results with overall unsatisfactory lymph node detection sensitivity.
Our preliminary approach to resolve this issue was to increase the amount of metal within the colloidal nanobeacons. Towards this aim, we prepared polymer-encapsulated gold nanobeacons (P-GNB 290 s) adopting a unique approach, which is based on the self-assembly of amphiphilic di-block copolymer in aqueous media to entrap high payloads of gold. In a typical synthesis, PS-b-PAA [19] [20] [21] [22] (Mn Â 10
À3
: 0.8-b-29.3, PDI ¼ 1.18, 0.0033 mmol) was dissolved in a mixture of methanol and CHCl 3 (4:1) and subjected to controlled evaporation under reduced pressure to generate a thin film of polymer (Fig. 1A) .
The thin film was dispersed in deionized water (0.2 mM) by probe sonication at ambient temperature. Octanethiol coated AuNPs (2% w/ v) were suspended in polysorbate (sorbitan monolaureate (5 vol%) and microfluidized with a PS-b-PAA dispersion (0.5 vol%) to obtain the P-GNB 290 particles. The nanobeacons were purified by exhaustive dialysis against an infinite sink of nanopure water using a cellulosic dialysis membrane (20 kDa MWCO). P-GNB 290 was characterized by multiple techniques. Hydrodynamic particle sizes for the P-GNB 290 were 289 AE 24 nm observed by dynamic light scattering measurements with narrow distribution (polydispersity indexes, PDI ¼ 0.15 AE 0.04) (Fig. 1B) . The particle stability and successful amphiline-encapsulation were confirmed by the presence of negative electrophoretic potential (z) values. Anhydrous state morphology of the particles was observed by atomic force microscopy (AFM) studies (Fig. 1C) . Gold content was determined by ICP-OES as 134 mg g
À1
, which corresponds to 71,493 gold metal atoms per nanobeacon.
Blood (i.e., hemoglobin), which produces a strong PA signal, is a source of intrinsic contrast inside the human body. Therefore, any material that is capable of generating PA signals comparable to blood has potential to serve as an extrinsic contrast agent. The use of the near infrared (NIR) window for PAT is well known for deep tissue imaging, although image contrast is reduced. Photoacoustic imaging of P-GNB 290 in suspension within the NIR range was promising. Fig. 2A shows P-GNB 290 (680 nM) produced a stronger PA signal than blood (l ¼ 767 nm). P-GNB 290 s produced a peak-to-peak PA signal amplitude of 540 AE 30 mV, whereas blood produced 133 AE 7 mV. Fig. 2B shows the PA spectrum over wavelengths from 721 to 823 nm. P-GNB 290 s produced a PA signal at least two times stronger than blood. The PA signal amplitude changed as the concentration of nanobeacons was varied. Fig. 2C shows how the PA signal amplitude changed for several laser wavelengths from serially diluted P-GNB 290 s. It is evident that a significant PA signal was produced even at the low concentration of 10 nM, making P-GNB 290 s a candidate for in vivo applications.
The potential of SLN imaging with the use of P-GNB 290 s was explored through forepaw injection in a rat model. Interestingly, SLN imaging with P-GNB 290 s (680 nM) was unsuccessful. Fig. 3C and D show the pre-(control) and post-injection (60 min) maximum amplitude projection (MAP) [8] photoacoustic images. SLNs were dynamically monitored for three days without promising results (n ¼ 4). This confirmed that we were not experiencing a slower, longer-lasting transport of these larger nanobeacons into the lymphatic vessels. These results led us to believe that the uptake of the P-GNB 290 s in the lymphatic channels and transport to the lymph node were poor, which presumably were correlated with the larger size and mass of these gold nanobeacons (>250 nm).
The unsuccessful outcome prompted us to explore a smaller lipidencapsulated (w90 nm) gold nanobeacon (L-GNB 90 ) (Fig. 1A) . Gold nanoparticles (AuNPs) were uniquely suspended within a polysorbate core matrix to avoid unfavorable interactions with the surrounding plasma proteins. In a typical procedure, octanethiolfunctionalized, coated AuNPs (2% w/v of inner matrix) were suspended in polysorbate (sorbitan monolaureate, 20 vol%) and homogenized with the surfactant mixture at 137.9 MPa for 4 min to produce L-GNB 90 s. The surfactant mixture comprised mainly of phosphatidylcholine (PC) (w90 mol% of lipid constituents). Hydrodynamic particle sizes for the L-GNB 90 s were 92 AE 12 nm (DLS) with narrow polydispersity indexes, PDI ¼ 0.35 AE 0.05 (Fig. 1B) . Anhydrous state particle heights were measured to be 45 AE 10 nm (Fig. 1C) . Gold content was determined by ICP-OES as 1.56 mg g À1 , corresponding to approximately 9 gold metal nanoparticles per L-GNB 90 s. Fig. 2 summarizes the feasibility of using L-GNB 90 s as NIR contrast agents. Fig. 2A shows that L-GNB 90 s (10 nM) produced a stronger PA signal than blood (l ¼ 767 nm). L-GNB 90 s produced a peak-to-peak PA signal amplitude of 168 AE 12 mV. Interestingly, L-GNB 90 s produced a stronger PA signal than blood below 795 nm wavelength but a weaker one above 800 nm. L-GNB 90 s produced weaker PA signals in suspension than P-GNB 290 s, presumably due to its incorporation of much lower concentrations of gold. Although L-GNB 90 s have a weaker absorption coefficient than P-GNB 290 s in the NIR wavelength range, they were still considered useful for in vivo SLN imaging application.
The efficacy of L-GNB 90 s for SLN imaging was studied in a rat model following intradermal injection of the particles, as used previously. At baseline, sagittal MAP photoacoustic image (resolution ¼ w500 mm, in plane) of the axillary area revealed a distinct microvasculature indicated by the red arrows (Fig. 3E) . Lymph nodes were undetectable at baseline, lacking any intrinsic optical absorbers, in contradistinction to the adjacent blood vessels containing highly absorbing red blood cells. Following baseline image acquisition, L-GNB 90 s (150 mL) were injected intradermally into the forepaw, and serial PA images were acquired. At 5 and 20 min postinjection, sentinel lymph nodes were easily visualized ( Fig. 3F and  G) . In Fig. 3F , immediately after the injection, L-GNB 90 s were noted traveling through the lymphatic system (designated by the blue arrow) and accumulating in the lymph nodes. At 20 min, the L-GNB 90 s had reached the SLNs and were no longer observed within the draining lymphatic vessel. Dynamic PA imaging was performed up to 1 h post-injection, and SLNs remained visible in all the PA images (see supporting information for more details). The blood vessels and the SLN were detected with a contrast of 12 and 89, respectively (calculated from the 1 h post-injection MAP image). The contrast is defined as the ratio of the average PA signal amplitude obtained from the blood vessel/SLN to the average background signal amplitude. Thus the contrast ratio between the SLN and the surrounding blood vessel was w7.5:1. The signal-to-noise ratio (SNR) was 24 dB and 39 dB for blood vessels and SLN, respectively. The SNR, calculated from the raw A-line signal without any signal averaging, was defined as 20 Â log (peak signal amplitude/standard deviation of background). Fig. 3H illustrates the same image as in Fig. 3G , with two different color maps (green for the contribution from the nanobeacons, red for hemoglobin). Some of the nanobeacons transited into the surrounding vessels, as evident from the signal therein. An optical photograph of the excised lymph node is shown in Fig. 3K . Subsequent dissection of the lymph node revealed no outwardly visible accumulation of AuNP themselves (i.e., red color) indicating the patent integrity of the surface lipid coating.
The above experiment was successfully repeated with diluted L-GNB 90 s (2.5 and 1 nM). In both cases, lymph nodes were clearly visible (Fig. 3I-J and M-N) in the post-injection (5 min) MAP photoacoustic image. We quantified the signal intensities and observed a w9 times enhancement with L-GNB 90 s injection, w7.5 times enhancement with 1/4Â diluted L-GNB 90 s, w5.2 times enhancement with 1/10Â diluted L-GNB 90 s, and w2.6 times enhancement with GNB 160 s. However, with P-GNB 290 s no signal enhancement was seen after injection (average signal is w1.01 times the pre-injection value). As a result, we concluded that SLNs mapping with P-GNB 290 s was infeasible. The total gold content of the excised lymph node specimens were analytically determined by ICP-OES as 8.74 mg g-1 and 1.99 mg g-1, (detection limit ¼ 0.02 mg g-1), for animals injected with L-GNB 90 s and P-GNB 290 s respectively.
Conclusions
In summary, both GNB 160 s and L-GNB 90 s can function as contrast agents for PA deep tissue imaging in the NIR window, with the smaller L-GNB 90 s being superior for SLNs detection. Although L-GNB 90 s had lower PAT contrast in suspension, in vitro than GNB 160 s or P-GNB 290 s, when injected intradermally L-GNB 90 s travel quickly through the lymphatic vessels and migrate exclusively to the lymph nodes. P-GNB 290 s produced strong PA signals in suspension and therefore could be beneficial for other in vivo application. These results suggest that cumulative nanoparticle deposition in lymph nodes is size dependent and that high payloads of gold, although offering greater contrast, may yield nanoagents with poor intradermal migration and lymphatic transport characteristics.
